[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-segmental-vitiligo-nsv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-segmental-vitiligo-nsv":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,72,100,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644667","ruxolitinib-cream-combined-with-corticosteroids-for-progressive-non-segmental-vitiligo-a-multicenter-real-world-study-100644667",false,"NCT07673640","Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study","Efficacy and Safety of Ruxolitinib Phosphate Cream Combined With Corticosteroids in Patients With Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study","Inclusion Criteria:\n\n* Age ≥ 12 years at the time of signing informed consent.\n* Clinical diagnosis of non-segmental vitiligo with facial involvement, and total body surface area (BSA) depigmentation ≤ 10%.\n* Diagnosed with progressive\u002Factive vitiligo meeting at least one of the following: Vitiligo Disease Activity (VIDA) score ≥ 3.\n\nClinical signs including trichrome vitiligo, confetti-like depigmentation, or Koebner phenomenon.\n\nThe extent of lesions under Wood's lamp is larger than that visible to the naked eye.\n\n* Agrees to have no pregnancy plans and uses effective contraception during the study and up to 4 weeks after the last dose.\n* Voluntarily signs the informed consent form and agrees to regular follow-up visits.\n\nExclusion Criteria:\n\n* Diagnosis of other clinical forms of vitiligo (e.g., segmental vitiligo).\n* Clinically diagnosed with stable vitiligo.\n* Co-existing skin depigmentation disorders affecting efficacy evaluation (e.g., pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macular hypomelanosis, nevus anemicus, chemical leukoderma, tinea versicolor).\n* Leukoderma lesions with more than 1\u002F3 white hair, or lesions accompanied by white hair where the investigator assesses the probability of benefit from participating is low based on clinical experience.\n* Contraindications to systemic corticosteroid use.\n* Known hypersensitivity or allergy to the study medications or excipients.\n* Known end-stage renal disease (ESRD) or currently undergoing renal replacement therapy (e.g., dialysis).\n* Concurrent participation in other clinical studies.\n* Any other condition which, in the investigator's judgment, makes the patient unsuitable for the study","ALL","12 Years",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","This study is a prospective, multicenter, real-world observational study to assess the clinical efficacy and safety of topical 1.5% Ruxolitinib phosphate cream used in combination with systemic corticosteroids in a real-world clinical setting. The study plans to observe patients aged 12 years and older with active, progressive non-segmental vitiligo involving the face. All treatments are prescribed based on standard routine clinical care and medical practice guidelines. Participants will apply Ruxolitinib cream twice daily to affected skin areas for up to 24 weeks alongside a standard corticosteroid regimen. The primary goal of the study is to evaluate how many patients achieve a 75% or greater improvement in their facial vitiligo patches after 12 weeks of combined treatment. Safety and side effects will also be closely monitored throughout the 24-week period.",[24],"Non-Segmental Vitiligo (NSV)",[26,27,28,29,30],"Ruxolitinib phosphate cream","Corticosteroid therapy","Multicenter study","Real-world study","Active Vitiligo","NOT_YET_RECRUITING","2026-06-30",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":20},"2026-06-20",{"date":39,"type":20},"2028-12-31",{"name":41,"class":42},"ShanShan Li","INDUSTRY",12,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100633925","phase-2-a-study-of-ly4005130-in-adult-participants-with-non-segmental-vitiligo-100633925","NCT07533019","A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo","A Phase 2, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Non-Segmental Vitiligo","Inclusion Criteria:\n\n* Eligible participants must have the following at both screening and baseline:\n\n  * A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months\n  * Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet\n  * BSA involvement of ≥0.5% on the face\n  * F-VASI ≥0.5 and T-VASI ≥3, and\n  * Either active or stable disease at both screening and baseline\n\nExclusion Criteria:\n\n* Participants who have other types of vitiligo that are not considered active or stable vitiligo\n* Currently have active forms of other disorders of pigmentation\n* Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions that would interfere with evaluation of vitiligo or response to treatment\n* Have a superficial skin infection within 2 weeks before baseline. Participants may be rescreened after the infection is resolved\n* Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year prior to screening\n* Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and\u002For unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking the study intervention or interfere with the interpretation of data\n* Any previous JAK inhibitor therapy, systemic or topical (for example, ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib) will NOT be allowed. Participant MUST be JAK inhibitor therapy-naïve","18 Years","75 Years",{"count":54,"type":20},60,"INTERVENTIONAL",[57],"PHASE2","The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm).\n\nBlood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.\n\nThe study will last approximately 48 weeks, including screening.",[60,24],"Vitiligo","RECRUITING","2026-06-19",{"date":64,"type":35},"2026-06-23",{"date":66,"type":35},"2026-04-14",{"date":68,"type":20},"2027-09",{"name":70,"class":42},"Eli Lilly and Company",35,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":55,"phases":83,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100640606","phase-2-a-phase-2-study-of-d-2570-in-subjects-with-non-segmental-vitiligo-100640606","NCT07625891","A Phase 2 Study of D-2570 in Subjects With Non-Segmental Vitiligo","A Phase 2 Multicenter, Randomized, Parallel-group,Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of D-2570 in Subjects With Non-Segmental Vitiligo","D2570-206","Inclusion Criteria:\n\n* Voluntarily signs informed consent and complies with study procedures.\n* Age 18-65 years, male or female.\n* Clinical diagnosis of non-segmental vitiligo at screening.\n* F-VASI ≥0.25 and T-VASI ≥5 at screening and baseline, with either active or stable vitiligo.\n* Women of childbearing potential have negative pregnancy tests at screening and baseline. All eligible subjects agree to effective contraception from consent through 30 days after last study drug dose.\n\nExclusion Criteria:\n\n* \\- Segmental, mixed vitiligo or other concurrent pigmentary\u002Factive skin disorders interfering with study assessment.\n* Over 33% facial or total vitiligo lesions with leukotrichia.\n* Pregnant or breastfeeding females.\n* Active, latent or inadequately treated tuberculosis infection.\n* Positive HIV, active HBV\u002FHCV infection, or untreated syphilis.\n* Current or history of severe herpes infection.\n* Severe systemic infection requiring recent inpatient, intravenous or oral anti-infective treatment.\n* Congenital or acquired immune deficiency, opportunistic infection history, or conditions requiring systemic immunosuppression during the study.\n* Uncontrolled thyroid disease, severe cardiovascular\u002Fcerebrovascular disease or other unstable severe systemic disorders.\n* Severe psychiatric disease, suicidal ideation, or alcohol\u002Fdrug abuse within 6 months.\n* Malignancy history within 5 years (excluding cured non-melanoma skin cancer and cervical intraepithelial neoplasia).\n* Gastrointestinal disease affecting drug absorption or major surgery within 8 weeks prior to dosing.\n* Clinically significant abnormal lab results: elevated liver\u002Frenal indices, decreased hemoglobin, WBC, platelet, lymphocyte or neutrophil counts.\n* History of severe drug hypersensitivity or drug-related toxicity.\n* Any condition that may impair protocol compliance or study participation per investigator judgment.","65 Years",{"count":82,"type":20},160,[57],"This study tests D-2570, an investigational drug, in people with non-segmental vitiligo to check its safety and effect on skin discoloration.\n\nEligible participants will take D-2570, or a placebo, once daily for 24 weeks in a double-blind setting. Most will then continue into a 24-week extension phase, where those on 27 mg or placebo will switch to one of the lower doses.\n\nAll participants will have a 4-week safety follow-up after treatment ends, with regular check-ups and blood tests throughout the study.",[60,24],[87,88,89],"Non-segmental Vitiligo","D-2570","Phase 2 Clinical Trial","2026-05-28",{"date":92,"type":35},"2026-06-04",{"date":94,"type":20},"2026-05-30",{"date":96,"type":20},"2028-05",{"name":98,"class":42},"InventisBio Co., Ltd",1,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":107,"targetDuration":4,"studyType":55,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":120,"locationsCount":4},"100635729","phase-2-evaluation-of-the-efficacy-and-safety-of-lw402-tablets-in-patients-with-non-segmental-vitiligo-100635729","NCT07556471","Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo","Inclusion Criteria:\n\n* Aged 18 to 75 years (inclusive), with no restriction on gender;\n* Clinically diagnosed with non-segmental vitiligo at screening;\n* At the screening visit and baseline visit, the Facial Vitiligo Area Scoring Index (F-VASI) is ≥ 0.5 and the Total Vitiligo Area Scoring Index (T-VASI) is ≥ 3;\n* At the screening visit and baseline visit, the disease is in the progressive stage or stable stage;\n\nExclusion Criteria:\n\n* Individuals with a known allergy to Janus kinase inhibitors；\n* Segmental vitiligo, mixed vitiligo, or undetermined vitiligo；\n* White hair is present in more than 33% of facial skin lesions due to vitiligo, or in more than 33% of total skin lesions due to vitiligo;\n* Skin lesions due to vitiligo are restricted to hairless areas, or hairless regions account for ≥30% of the lesion sites (e.g., lips, palms, fingers, labia);\n* Individuals with other active hypopigmentary conditions during the screening period (including but not limited to Vogt-Koyanagi-Harada syndrome, hypopigmentation associated with malignant tumors \\[melanoma and mycosis fungoides\\], post-inflammatory hypopigmentation, pityriasis alba \\[a mild manifestation of atopic dermatitis\\], senile leukoderma \\[age-related depigmentation\\], chemical\u002Fdrug-induced leukoderma, ataxia-telangiectasia, tuberous sclerosis complex, melasma, and congenital hypopigmentary disorders \\[including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, hereditary symmetrical dyschromatosis, xeroderma pigmentosum, and nevus depigmentosus\\]) are excluded. Note: Coexisting halo nevus (also referred to as Sutton nevus) is permitted;",{"count":108,"type":20},180,[57],"This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to assess the efficacy, safety, and tolerability of LW402 tablets in participants with non-segmental vitiligo.\n\nDrawing on the prior\u002Fpreclinical data of LW402 tablets, this clinical trial will incorporate three dose groups: 50 mg twice daily (BID), 100 mg BID, and 150 mg BID. The trial will be structured into a screening period (maximum 5 weeks), a treatment period (52 weeks, encompassing a 24-week main trial phase and a 28-week extension phase), and a safety follow-up period (4 weeks). The maximum duration of participation in this study will be 61 weeks.\n\nFollowing the completion of 24-week data collection for all trial participants, unblinding will be performed in accordance with the pre-specified procedure. Subsequently, based on the unblinded data results, regulatory communication will be conducted with the Center for Drug Evaluation (CDE) regarding the initiation of the Phase III confirmatory clinical trial. Participants who have undergone unblinding will continue to attend scheduled study visits to complete the trial.",[24],[113],"LW402 Tablets,Phase II,Non-segmental Vitiligo","2026-04-28",{"date":116,"type":35},"2026-04-29",{"date":118,"type":20},"2026-05-31",{"date":39,"type":20},{"name":121,"class":42},"Shanghai Longwood Biopharmaceuticals Co., Ltd.",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100603434","a-real-world-study-to-globally-assess-disease-burden-in-adolescent-and-adult-participants-with-alopecia-areata-vitiligo-or-hidradenitis-suppurativa-100603434","NCT07136467","A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa","Multi-Country, Cross-sectional Study to Characterize Real World Burden of Disease in Adolescent and Adult Patients With Alopecia Areata, Vitiligo or Hidradenitis Suppurativa (MEASURE AAVitHS)","MEASUREAAVitHS","Inclusion Criteria:\n\n* Participants with Physician-confirmed diagnosis of non-segmental vitiligo (NSV), moderate to severe Alopecia Areata (AA), or moderate to severe hidradenitis suppurativa (HS)\n* Participants Ability to understand study questionnaires, with caregiver support as required for adolescents\n\nExclusion Criteria:\n\n* Participating in interventional clinical trial(s) at time of study visit (participation in another non-interventional study or registry does not exclude a participant from this study)\n* Unable or unwilling to comply with study requirements and PRO collection",{"count":131,"type":20},2795,"This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.",[24,134,135],"Alopecia Areata","Hidradenitis Suppurativa",[24,134,135],"2026-02-12",{"date":139,"type":35},"2026-02-13",{"date":141,"type":35},"2025-09-02",{"date":143,"type":20},"2027-08",{"name":145,"class":42},"AbbVie",116]